


## Appendix A

### Claim Amendments

1. (Currently amended) A compound of formula 1



(1)

in which

R1 is hydrogen, 1-4C-alkyl or hydroxy-1-4C-alkyl,

R2 is hydrogen, 1-4C-alkyl, hydroxy-1-4C-alkyl, halogen, 2-4C-alkenyl or 2-4C-alkynyl,


R3 is hydrogen, halogen, trifluoromethyl, 1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, carboxyl, -CO-1-4C-alkoxy, hydroxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, fluoro-1-4C-alkoxy-1-4C-alkyl or the radical -CO-NR3aR3b,

one of the substituents R4a and R4b is hydrogen and the other is hydroxyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-

alkoxy, 1-4C-alkylcarbonyloxy or the radical R4', or  
in which R4a and R4b together are O (oxygen),  
where R4' is a radical from which a hydroxyl group is  
formed under physiological conditions,  
one of the substituents R5a and R5b is hydrogen and the  
other is hydrogen, hydroxyl, 1-4C-alkoxy, 1-4C-alkoxy-  
1-4C-alkoxy, 1-4C-alkylcarbonyloxy or the radical R5',  
or in which R5a and R5b together are O (oxygen),  
where R5' is a radical from which a hydroxyl group is  
formed under physiological conditions,  
where one of the substituents R4a and R4b must have the  
meaning R4' and/or one of the substituents R5a and R5b  
must have the meaning R5',  
R6 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-  
alkoxycarbonylamino, 1-4C-alkoxy-1-4C-  
alkoxycarbonylamino or trifluoromethyl,  
R7 is hydrogen, halogen, 1-4C-alkyl or 1-4C-alkoxy and  
X is O (oxygen) or NH,  
where R3a is hydrogen, 1-7C-alkyl, hydroxy-1-4C-alkyl or 1-  
4C-alkoxy-1-4C-alkyl and  
R3b is hydrogen, 1-7C-alkyl, hydroxy-1-4C-alkyl or 1-4C-  
alkoxy-1-4C-alkyl,

or where R3a and R3b together, including the nitrogen atom to which both are bonded, are a pyrrolidino, piperidino or morpholino radical, ~~or its salts~~ or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

2. (Currently amended) A compound of the formula 1 ~~as claimed in claim 1,~~



in which

R1 is 1-4C-alkyl,

R2 is 1-4C-alkyl or hydroxy-1-4C-alkyl,

R3 is hydrogen, halogen, carboxyl, -CO-1-4C-alkoxy, hydroxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, fluoro-1-4C-alkoxy-1-4C-alkyl or the radical -CO-NR3aR3b,

one of the substituents R4a and R4b is hydrogen and the other is hydroxyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkoxy or the radical -OR', or in which R4a and R4b together are O (oxygen),

one of the substituents R5a and R5b is hydrogen and the other is hydroxyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkoxy or the radical -OR', or in which R5a and R5b together are O (oxygen),

where one of the substituents R4a and R4b must have the meaning -OR' and/or one of the substituents R5a and R5b must have the meaning -OR',

R6 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxycarbonylamino, 1-4C-alkoxy-1-4C-alkoxycarbonylami- no or trifluoromethyl,

R7 is hydrogen, halogen, 1-4C-alkyl or 1-4C-alkoxy and

X is O (oxygen) or NH,

where

R3a is hydrogen, 1-7C-alkyl, hydroxy-1-4C-alkyl or 1-4C-alkoxy-1-4C-alkyl and

R3b is hydrogen, 1-7C-alkyl, hydroxy-1-4C-alkyl or 1-4C-alkoxy-1-4C-alkyl, or where

R3a and R3b together, including the nitrogen atom to which both are bonded, are a pyrrolidino, piperidino or morpholino radical,

and where

R' is selected from the group consisting of

-C(O)-NR<sub>8</sub>R<sub>9</sub>,  
-C(O)-alk-NR<sub>8</sub>R<sub>9</sub>,  
-C(O)-alk-C(O)-NR<sub>8</sub>R<sub>9</sub>,  
-P(O)(OH)<sub>2</sub>,  
-S(O)<sub>2</sub>NR<sub>8</sub>R<sub>9</sub>,  
-C(O)-R<sub>8</sub>,  
-C(O)-C<sub>6</sub>H<sub>3</sub>R<sub>10</sub>R<sub>11</sub>,  
-C(O)-OR<sub>8</sub>,  
-C(O)-alk-C(O)-R<sub>8</sub>,  
-C(O)-alk-C(O)-OR<sub>8</sub>,  
-C(O)-C(O)-R<sub>8</sub>,  
-C(O)-C(O)-OR<sub>8</sub> and  
-CH<sub>2</sub>-OR<sub>8</sub>,

where

alk is 1-7C-alkylene,

R<sub>8</sub> is hydrogen, 1-10C-alkyl or 1-4C-alkyl substituted by  
halogen, carboxyl, hydroxyl, sulfo (-SO<sub>3</sub>H), sulfamoyl  
(-SO<sub>2</sub>NH<sub>2</sub>), carbamoyl (-CONH<sub>2</sub>), 1-4C-alkoxy or 1-4C-  
alkoxycarbonyl,


R<sub>9</sub> is hydrogen or 1-4C-alkyl,

R<sub>10</sub> is hydrogen, halogen, nitro, 1-4C-alkyl, 1-4C-alkoxy,  
1-4C-alkoxycarbonyl, 1-4C-alkoxycarbonylamino, 1-4C-

alkoxy-1-4C-alkoxycarbonylamino or trifluoromethyl ~~and~~  
and

R11 is hydrogen, halogen, 1-4C-alkyl or 1-4C-alkoxy, [[.]]  
~~or its salts~~  
or a hydrate, solvate, salt, hydrate of a salt or solvate  
of a salt thereof.

3. (Currently amended) A compound as claimed in claim  
± 2, having the formula 1\*



1\*

in which

R1 is 1-4C-alkyl,

R2 is 1-4C-alkyl,

R3 is hydrogen, chlorine, fluorine, hydroxymethyl, difluoromethoxymethyl or the radical -CO-NR3aR3b, one of the substituents R4a and R4b is hydrogen and the other is hydroxyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkoxy or the radical -OR', or in which R4a and R4b together are O (oxygen), one of the substituents R5a and R5b is hydrogen and the other is hydroxyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkoxy or the radical -OR', or in which R5a and R5b together are O (oxygen), where one of the substituents R4a and R4b must have the meaning -OR' and/or one of the substituents R5a and R5b must have the meaning -OR', R6 is hydrogen, R7 is hydrogen and X is O (oxygen) or NH, where R3a is hydrogen, 1-4C-alkyl, hydroxy-1-4C-alkyl or 1-4C-alkoxy-1-4C-alkyl and R3b is hydrogen, 1-4C-alkyl, hydroxy-1-4C-alkyl or 1-4C-alkoxy-1-4C-alkyl, and where R' is selected from the group consisting of -C(O)-NR8R9,

-C(O)-alk-NR<sub>8</sub>R<sub>9</sub>,  
-C(O)-alk-C(O)-NR<sub>8</sub>R<sub>9</sub>,  
-P(O)(OH)<sub>2</sub>,  
-S(O)<sub>2</sub>NR<sub>8</sub>R<sub>9</sub>,  
-C(O)-R<sub>8</sub>,  
-C(O)-C<sub>6</sub>H<sub>3</sub>R<sub>10</sub>R<sub>11</sub>,  
-C(O)-OR<sub>8</sub> ,  
-C(O)-alk-C(O)-OR<sub>8</sub>,  
-C(O)-C(O)-OR<sub>8</sub> and  
-CH<sub>2</sub>-OR<sub>8</sub>,

where

alk is 1-7C-alkylene,

R<sub>8</sub> is hydrogen, 1-10C-alkyl or 1-4C-alkyl substituted by  
carboxyl or sulfo (-SO<sub>3</sub>H),

R<sub>9</sub> is hydrogen or 1-4C-alkyl,

R<sub>10</sub> is hydrogen, halogen, nitro, 1-4C-alkyl, 1-4C-alkoxy,  
1-4C-alkoxycarbonyl, 1-4C-alkoxycarbonylamino, 1-4C-  
alkoxy-1-4C-alkoxycarbonylamino or trifluoromethyl and

R<sub>11</sub> is hydrogen, halogen, 1-4C-alkyl or 1-4C-alkoxy, ~~or its~~  
~~salts of the compounds~~

or a hydrate, solvate, salt, hydrate of a salt or solvate  
of a salt thereof.



4. (Currently amended) A compound as claimed in claim  
± 2, which has the formula 1\* in claim 3,

in which

R1 is methyl,

R2 is methyl,

R3 is hydrogen, chlorine, fluorine, hydroxymethyl,  
difluoromethoxymethyl or the radical -CO-NR3aR3b,

one of the substituents R4a and R4b is hydrogen and the  
other is 1-4C-alkoxy or 1-4C-alkoxy-1-4C-alkoxy,

one of the substituents R5a and R5b is hydrogen and the  
other is the radical -OR',

R6 is hydrogen,

R7 is hydrogen and

X is O (oxygen) or NH,

where

R3a is hydrogen, methyl, ethyl, propyl, 2-hydroxyethyl or  
2-methoxyethyl and

R3b is hydrogen, methyl or ethyl,

and where

R' is selected from the group consisting of

-C(O)-NR8R9,

-C(O)-alk-NR8R9,

-C(O)-alk-C(O)-NR8R9,

-P(O)(OH)<sub>2</sub>,

-S(O)<sub>2</sub>NR<sub>8</sub>R<sub>9</sub>,  
-C(O)-R<sub>8</sub>,  
-C(O)-C<sub>6</sub>H<sub>3</sub>R<sub>10</sub>R<sub>11</sub>,  
-C(O)-OR<sub>8</sub>,  
-C(O)-alk-C(O)-OR<sub>8</sub>,  
-C(O)-C(O)-OR<sub>8</sub> and  
-CH<sub>2</sub>-OR<sub>8</sub>,

where

alk is 1-7C-alkylene,

R<sub>8</sub> is hydrogen, 1-10C-alkyl or 1-4C-alkyl substituted by  
carboxyl or sulfo (-SO<sub>3</sub>H),

R<sub>9</sub> is hydrogen or 1-4C-alkyl,

R<sub>10</sub> is hydrogen, halogen, nitro, 1-4C-alkyl, 1-4C-alkoxy,  
1-4C-alkoxycarbonyl or trifluoromethyl and

R<sub>11</sub> is hydrogen or halogen,

~~or the salts of the compound~~

or a hydrate, solvate, salt, hydrate of a salt or solvate  
of a salt thereof.

5. (Original) A compound as claimed in claim 4, in  
which R' has the meaning -C(O)-N(CH<sub>3</sub>)<sub>2</sub>, -C(O)-N(C<sub>2</sub>H<sub>5</sub>)<sub>2</sub>, -  
C(O)-NHC<sub>2</sub>H<sub>5</sub>, -C(O)-CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -C(O)-(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>, -C(O)-  
C(CH<sub>3</sub>)<sub>2</sub>NH<sub>2</sub>, -C(O)-CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>, -C(O)-CH(NH<sub>2</sub>)-CH(CH<sub>3</sub>)<sub>2</sub>, -C(O)-  
CH(NH<sub>2</sub>)CH(CH<sub>3</sub>)C<sub>2</sub>H<sub>5</sub>, -C(O)-(CH<sub>2</sub>)<sub>6</sub>C(O)N(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>2</sub>SO<sub>3</sub>H, -

$P(O)(OH)_2$ ,  $-S(O)_2NH_2$ ,  $-C(O)-H$ ,  $-C(O)-C(CH_3)_3$ ,  $-C(O)-CH_2CH_2COOH$ ,  $-C(O)-CH_3$ ,  $-C(O)-C_2H_5$ ,  $-C(O)-CH_2OCH_3$ ,  $-C(O)-C_6H_5$ ,  $-C(O)-C_6H_4-4-NO_2$ ,  $-C(O)-C_6H_4-3-NO_2$ ,  $-C(O)-C_6H_4-4-OCH_3-$ ,  $-C(O)-C_6H_4-4-C(O)-OCH_3$ ,  $-C(O)-OCH_3$ ,  $-C(O)-O$ -menthyl,  $-C(O)-CH_2-C(O)-OCH_3$ ,  $-C(O)-CH_2CH_2-C(O)-OCH_3$ ,  $-C(O)-C(O)-OCH_3$ ,  $-C(O)-C(O)-OC_2H_5$  or  $-CH_2OCH(CH_3)_2$ .

6. (Currently amended) A compound as claimed in claim ± 2, which has the formula 1\* in claim 3,

in which

R1 is methyl,

R2 is methyl,

R3 is hydrogen, chlorine, fluorine, hydroxymethyl, difluoromethoxymethyl or the radical  $-CO-NR_{3a}R_{3b}$ ,

one of the substituents R4a and R4b is hydrogen and the other is 1-4C-alkoxy or 1-4C-alkoxy-1-4C-alkoxy,

R5a is the radical  $-OR'$ ,

R5b is hydrogen,

R6 is hydrogen,

R7 is hydrogen and

X is O (oxygen) or NH,

where

R3a is hydrogen, methyl, ethyl, propyl, 2-hydroxyethyl or 2-methoxyethyl and

R3b is hydrogen, methyl or ethyl,

and where

R' is selected from the group consisting of

-C(O)-NR<sub>8</sub>R<sub>9</sub>,

-C(O)-alk-NR<sub>8</sub>R<sub>9</sub>,

-C(O)-R<sub>8</sub>,

-C(O)-C<sub>6</sub>H<sub>3</sub>R<sub>10</sub>R<sub>11</sub>,

-C(O)-OR<sub>8</sub>,

-C(O)-alk-C(O)-OR<sub>8</sub>, and

-C(O)-C(O)-OR<sub>8</sub>,

where

alk is 1-4C-alkylene,

R<sub>8</sub> is hydrogen, 1-10C-alkyl or 1-4C-alkyl substituted by 1-4C-alkoxy,

R<sub>9</sub> is hydrogen or 1-4C-alkyl,

R<sub>10</sub> is hydrogen, halogen, nitro, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl or trifluoromethyl and

R<sub>11</sub> is hydrogen or halogen,

~~or its salts~~

or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

7. (Currently amended) A compound as claimed in claim  
± 2, which has the formula 1\* in claim 3,

in which

R1 is methyl,

R2 is methyl,

R3 is hydrogen,

one of the substituents R4a and R4b is hydrogen and the

other is 1-4C-alkoxy or 1-4C-alkoxy-1-4C-alkoxy,

R5a is the radical -OR',

R5b is hydrogen,

R6 is hydrogen,

R7 is hydrogen and

X is O (oxygen) or NH,

where

R' is selected from the group consisting of

-C(O)-NR8R9,

-C(O)-alk-NR8R9,

-C(O)-R8,

-C(O)-C6H3R10R11,

-C(O)-OR8,

-C(O)-alk-C(O)-OR8, and

-C(O)-C(O)-OR8,

where

alk is 1-4C-alkylene,

R8 is hydrogen, 1-10C-alkyl or 1-4C-alkyl substituted by 1-4C-alkoxy,

R9 is hydrogen or 1-4C-alkyl,

R10 is hydrogen, nitro, 1-4C-alkoxy or 1-4C-alkoxycarbonyl and

R11 is hydrogen,

~~or its salts~~

or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

8. (Original) A compound as claimed in claim 7, in which R' has the meaning  $-C(O)-N(CH_3)_2$ ,  $-C(O)-N(C_2H_5)_2$ ,  $-C(O)-NHC_2H_5$ ,  $-C(O)-CH_2N(CH_3)_2$ ,  $-C(O)-H$ ,  $-C(O)-CH_3$ ,  $-C(O)-C_2H_5$ ,  $-C(O)-CH_2OCH_3$ ,  $-C(O)-C_6H_5$ ,  $-C(O)-C_6H_4-4-NO_2$ ,  $-C(O)-C_6H_4-3-NO_2$ ,  $-C(O)-C_6H_4-4-OCH_3$ ,  $-C(O)-C_6H_4-4-C(O)-OCH_3$ ,  $-C(O)-OCH_3$ ,  $-C(O)-O-menthyl$ ,  $-C(O)-CH_2-C(O)-OCH_3$ ,  $-C(O)-CH_2CH_2-C(O)-OCH_3$ ,  $-C(O)-C(O)-OCH_3$  or  $-C(O)-C(O)-OC_2H_5$ .

9. (Currently amended) A ~~medicament~~ pharmaceutical composition comprising a compound as claimed in claim 1 and/or a ~~pharmacologically tolerable~~ pharmaceutically acceptable hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof together with ~~customary~~

~~pharmaceutical auxiliaries and/or excipients~~ a  
pharmaceutically acceptable auxiliary or excipient.

10. (Currently amended) A method of preventing or  
treating a gastrointestinal disease in a patient comprising  
administering to a patient in need thereof a  
therapeutically effective amount of ~~The use of compounds a~~  
compound as claimed in claim 1 and their pharmacologically  
~~tolerable salts for the prevention and treatment of~~  
gastrointestinal diseases or a pharmaceutically acceptable  
hydrate, solvate, salt, hydrate of a salt or solvate of a  
salt thereof.

11. (New) A compound which is selected from the group  
consisting of:

(7S,8R,9R)-8-Acetoxy-7-(2-methoxyethoxy)-2,3-dimethyl-  
9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]  
naphthyridine;

(7R,8R,9R)-8-Acetoxy-7-(2-methoxyethoxy)-2,3-dimethyl-  
9-phenyl-7,8,9,10-tetrahydroimidazo[1,2h][1,7]  
naphthyridine;

(7R,8R,9R)-8-Acetoxy-7-methoxy-2,3-dimethyl-9-phenyl-  
7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine;

(7R,8R,9R)-8-Acetoxy-7-ethoxy-2,3-dimethyl-9-phenyl-  
7,8,9,10-tetrahydroimidazo-[1,2-h][1,7]naphthyridine;

(7R,8R,9R)-7-(2-Methoxyethoxy)-2,3-dimethyl-9-phenyl-  
8-propionyloxy-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]  
naphthyridine;

(7R,8R,9R)-8-Benzoyloxy-7-(2-methoxyethoxy)-2,3-  
dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]  
naphthyridine;

(7S,8R,9R)-8-Benzoyloxy-7-(2-methoxyethoxy)-2,3-  
dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]  
naphthyridine;

(7R,8R,9R)-8-Methoxycarbonyloxy-7-(2-methoxyethoxy)-  
2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-  
h][1,7]naphthyridine;

(7S,8R,9R)-8-Methoxycarbonyloxy-7-(2-methoxyethoxy)-  
2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-  
h][1,7]naphthyridine;

(7R,8R,9R)-8-Benzoyloxy-7-methoxy-2,3-dimethyl-9-  
phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine;

(7S,8R,9R)-8-Benzoyloxy-7-methoxy-2,3-dimethyl-9-  
phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine;

(7R,8R,9R)-7-(2-Methoxyethoxy)-2,3-dimethyl-8-(4-  
nitrobenzoyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-  
h][1,7]naphthyridine;



(7S, 8R, 9R) -7-(2-Methoxyethoxy)-2,3-dimethyl-8-(4-nitrobenzoyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine;

(7S, 8R, 9R) -7-(2-Methoxyethoxy)-2,3-dimethyl-8-(3-nitrobenzoyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine;

(7R, 8R, 9R) -7-(2-Methoxyethoxy)-2,3-dimethyl-8-(3-nitrobenzoyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine;

(7S, 8R, 9R) -7-Methoxy-2,3-dimethyl-8-(3-nitrobenzoyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine;

(7R, 8R, 9R) -7-Methoxy-2,3-dimethyl-8-(3-nitrobenzoyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine;

(7S, 8R, 9R) -7-(2-Methoxyethoxy)-2,3-dimethyl-8-(4-methoxybenzoyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine;

(7R, 8R, 9R) -7-(2-Methoxyethoxy)-2,3-dimethyl-8-(4-methoxybenzoyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine;

(7S, 8R, 9R) -7-(2-Methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethylcarbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine;

(7S, 8R, 9R) -7- (2-Methoxyethoxy) -8- (N, N-diethylaminocarbonyloxy) -2, 3-dimethyl-9-phenyl-7, 8, 9, 10-tetrahydroimidazo[1, 2-h][1, 7]naphthyridine;

(7R, 8R, 9R) -7- (2-Methoxyethoxy) -8- (N, N-diethylaminocarbonyloxy) -2, 3-dimethyl-9-phenyl-7, 8, 9, 10-tetrahydroimidazo[1, 2-h][1, 7]naphthyridine;

(7R, 8R, 9R) -8-Ethylaminocarbonyloxy-7- (2-methoxyethoxy) -2, 3-dimethyl-9-phenyl-7, 8, 9, 10-tetrahydroimidazo[1, 2-h][1, 7]naphthyridine;

(7S, 8R, 9R) -8-Ethylaminocarbonyloxy-7- (2-methoxyethoxy) -2, 3-dimethyl-9-phenyl-7, 8, 9, 10-tetrahydroimidazo[1, 2-h][1, 7]naphthyridine;

(7R, 8R, 9R) -8- [ (+) -Menthylloxycarbonyloxy] -7- (2-methoxyethoxy) -2, 3-dimethyl-9-phenyl-7, 8, 9, 10-tetrahydroimidazo[1, 2-h][1, 7]naphthyridine;

(7S, 8R, 9R) -8- [ (+) -Menthylloxycarbonyloxy] -7- (2-methoxyethoxy) -2, 3-dimethyl-9-phenyl-7, 8, 9, 10-tetrahydroimidazo[1, 2-h][1, 7]naphthyridine;

(7R, 8R, 9R) -7- (2-Methoxyethoxy) -8- (0-methylsuccinoyloxy) -2, 3-dimethyl-9-phenyl-7, 8, 9, 10-tetrahydroimidazo[1, 2-h][1, 7]naphthyridine;

(7S, 8R, 9R) -7- (2-Methoxyethoxy) -8- (0-methylsuccinoyloxy) -2, 3-dimethyl-9-phenyl-7, 8, 9, 10-tetrahydroimidazo[1, 2-h][1, 7]naphthyridine;

(7R,8R,9R)-7-(2-Methoxyethoxy)-8-(0-methylmalonyloxy)-  
2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-  
h][1,7]naphthyridine;

(7S,8R,9R)-7-(2-Methoxyethoxy)-8-(0-methylmalonyloxy)-  
2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-  
h][1,7]naphthyridine;

(7R,8R,9R)-7-(2-Methoxyethoxy)-8-(0-ethyloxaloyloxy)-  
2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-  
h][1,7]naphthyridine;

(7S,8R,9R)-8-(0-Ethyloxaloyloxy)-7-(2-methoxyethoxy)-  
2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-  
h][1,7]naphthyridine;

(7R,8R,9R)-8-Formyloxy-(2-methoxyethoxy)-2,3-dimethyl-  
9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]  
naphthyridine;

(7S,8R,9R)-8-Formyloxy-(2-methoxyethoxy)-2,3-dimethyl-  
9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]  
naphthyridine;

(7R,8R,9R)-8-Benzoyloxy-2,3-dimethyl-7-(2-  
methoxyethoxy)-9-phenyl-7H-8,9-dihydropyrano[2,3-  
c]imidazo[1,2-a]pyridine;

(7S,8R,9R)-8-Benzoyloxy-2,3-dimethyl-7-(2-methoxy-  
ethoxy)-9-phenyl-7H-8,9-dihydropyrano[2,3-c]imidazo[1,2-  
a]pyridine;

(7R,8R,9R)-8-[4-(Methoxycarbonyl)-benzoyloxy]-2,3-dimethyl-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydropyrano[2,3-c]imidazo[1,2-a]pyridine;

(7S,8R,9R)-8-[4-(Methoxycarbonyl)-benzoyloxy]-2,3-dimethyl-7-(2-methoxyethoxy)-9-phenyl-7H-8,9-dihydropyrano[2,3-c]imidazo[1,2-a]pyridine;

(7S,8R,9R)-2,3-Dimethyl-7-methoxy-8-methoxyacetyloxy-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine;

(7R,8R,9R)-8-(N,N-Diethylaminocarbonyloxy)-2,3-dimethyl-7-methoxy-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine;

(7S,8R,9R)-8-(N,N-Diethylaminocarbonyloxy)-2,3-dimethyl-7-methoxy-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine;

(7R,8R,9R)-7-Methoxy-8-methoxycarbonyloxy-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine;

(7S,8R,9R)-7-Methoxy-8-methoxycarbonyloxy-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine;

(7R,8R,9R)-2,3-Dimethyl-8-formyloxy-7-methoxy-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine;

(7S,8R,9R)-2,3-Dimethyl-8-formyloxy-7-methoxy-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine;  
(7R,8R,9R)-8-Benzoyloxy-2,3-dimethyl-7-methoxy-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine;  
and hydrates, solvates, salts, hydrates of the salts and solvates of the salts thereof.

12. (New) A compound which is (7R,8R,9R)-7-(2-Methoxyethoxy)-2,3-dimethyl-8-(N,N-dimethylaminomethyl-carbonyloxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine, or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof.

13. (New) A pharmaceutical composition comprising a compound as claimed in claim 2 and/or a pharmaceutically acceptable hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof together with a pharmaceutically acceptable auxiliary or excipient.

14. (New) A method of preventing or treating a gastrointestinal disease in a patient comprising administering to a patient in need thereof a therapeutically effective amount of a compound as claimed in claim 2 or a pharmaceutically acceptable hydrate,

solvate, salt, hydrate of a salt or solvate of a salt  
thereof.